✦ LIBER ✦

Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer

✍ Scribed by Kim, Jung Han; Kim, Hyeong Su; Choi, Jong Soo; Lee, Kyung Min; Shin, Young Chul; Ahn, Byung Moo; Choi, Dae Ro; Kwon, Jung Hye; Park, Sarah; Kim, Ho Young; Jung, Joo Young; Kim, Hyo Jung; Song, Hun Ho; Zang, Dae Young

Book ID: 119320042
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 313 KB
Volume: 64
Category: Article
ISSN: 0169-5002
DOI: 10.1016/j.lungcan.2008.10.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparison of adverse events and efficac

Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis

✍ Tsukasa Yoshida, Kazuhiko Yamada, Koichi Azuma, Akihiko Kawahara, Hideyuki Abe, 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 225 KB

Bilateral subdural hemorrhage as a serio

Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia

✍ Yhim, Ho-Young; Kim, Hee Sun; Lee, Na-Ri; Song, Eun-Kee; Kwak, Jae-Yong; Yim, Ch 📂 Article 📅 2012 🏛 Carden Jennings Publishing 🌐 English ⚖ 174 KB

A population-based study of gefitinib in

A population-based study of gefitinib in patients with non-small cell lung cancer

✍ Kenji Hayashibara; Hiroaki Satoh; Yoko Shinohara; Masaharu Inagaki; Takayuki Kab 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 224 KB

Rationale of a relaunch of gefitinib in

Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients

✍ Pircher, Andreas; Ploner, Ferdinand; Popper, Helmut; Hilbe, Wolfgang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Gefitinib in patients with non-small cel

Gefitinib in patients with non-small cell lung cancer: Symptomatic improvement within a few days

✍ Bearz, A.; Vaccher, E.; Spazzapan, S.; Berretta, M.; Tirelli, U. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Differences in adverse events between 25

Differences in adverse events between 250mg daily gefitinib and 150mg daily erlotinib in Japanese patients with non-small cell lung cancer

✍ Togashi, Yosuke; Masago, Katsuhiro; Fujita, Shiro; Hatachi, Yukimasa; Fukuhara, 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 182 KB